United States securities and exchange commission logo





                              June 30, 2020

       Alan Collier
       Chief Executive Officer
       ENDONOVO THERAPEUTICS, INC.
       6320 Canoga Avenue, 15th Floor
       Woodland Hills, CA 91367

                                                        Re: ENDONOVO
THERAPEUTICS, INC.
                                                            Registration
Statement on Form S-1
                                                            Filed June 23, 2020
                                                            File No. 333-239384

       Dear Mr. Collier:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comments. In some of our comments, we may ask you to
provide us with
       information so we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1 filed June 23, 2020

       Index to Consolidated Financial Statements, page 47

   1.                                                   Please amend to include
the Report of Independent Registered Public Accounting Firm
                                                        that you refer to on
page 46 for the audited financial statement periods presented in the
                                                        filing pursuant to Rule
2-02 of Regulation S-X.
       Exhibits

   2.                                                   We note that Exhibit
23.1 is missing the accounting firm's signature. Please re-file the
                                                        exhibit including this
item with your next amendment.

              We remind you that the company and its management are responsible
for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
 Alan Collier
ENDONOVO THERAPEUTICS, INC.
June 30, 2020
Page 2

action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Jason L. Drory at 202-551-8342 or Dorrie Yale at
202-551-8776 with any
questions.



                                                           Sincerely,
FirstName LastNameAlan Collier
                                                           Division of
Corporation Finance
Comapany NameENDONOVO THERAPEUTICS, INC.
                                                           Office of Life
Sciences
June 30, 2020 Page 2
cc:       Frank J. Hariton, Esq.
FirstName LastName